Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022
- Author(s)
- Hitchen, N; Shahnam, A; Manoharan, S; Topp, M; Mileshkin, L; Lim, AM; Whittle, JR; Luen, SJ; Solomon, B; Lackovic, K; Desai, J; Tran, B;
- Journal Title
- Asia Pacific Journal of Clinical Oncology
- Publication Type
- Jun 24 epub ahead of print
- Abstract
- BACKGROUND: Phase 1 oncology trials provide access to new therapies and may improve cancer outcomes. Phase 1 trials conducted in the Asian-Pacific region are increasing at a faster rate than the global trend. This study aimed to describe the changing landscape of phase 1 oncology trials in Australia in the last decade. METHODS: This cross-sectional study reviewed phase 1 oncology trials registered on ClinicalTrials.gov conducted in Australia. Phase 1 trials were included for analysis if they enrolled adults with solid organ malignancies, used at least one systemic agent, and were first registered between January 1, 2012, and December 31, 2022. The number of trials, site locations, sponsor type, and drug class were analyzed using descriptive statistics. RESULTS: Over the 10-year period, ClinicalTrials.gov included 493 phase 1 clinical trials across 71 Australian sites. Most sites were in metropolitan locations; in Melbourne, trials were concentrated within selected sites, while in Sydney, trials were spread across a larger number of sites. The number of phase 1 trials per annum increased from 18 in 2012 to 75 in 2022. Since 2020, emerging biopharmaceutical companies have become the predominant sponsor type, a trend that is also seen globally. While most trial sponsors were North American (42%), there was increasing representation from Asian sponsors over the 10-year period (6% in 2012 to 39% in 2022). Immunomodulatory (45%) and targeted approaches (44%) accounted for most drug classes used alone or in combination. CONCLUSIONS: There are an increasing number of phase 1 trials conducted within Australia. Sponsors of phase 1 trials are increasingly from Asian countries and are more likely to be emerging biopharmaceutical companies.
- Publisher
- Wiley
- Keywords
- Australia; cancer; early phase; oncology
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 38923830
- Publisher's Version
- https://doi.org/10.1111/ajco.14100
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-06-28 10:39:04
Last Modified: 2024-06-28 03:27:43